UK Rebate Mechanism Could Force Market Withdrawals, Warns BGMA

Billions of pounds in lost savings for the UK National Health Service are at stake due to expected reduced competition in branded generics and biosimilars, stemming from a UK rebate mechanism designed to increase access to new treatments and promote affordability, according to a new study cited by the British Generic Manufacturers Association.

Claiming that the rising rebate rate “is forcing manufacturers to shun the UK market, further reducing price competition,” the BGMA called for branded generics and biosimilars to be made exempt from the Voluntary Scheme for Branded Medicines Pricing and Access, agreement